摘要
宫颈癌是女性常见恶性肿瘤,全球发病率仅次于乳腺癌,患者预后较差。据统计显示,宫颈癌患者中位生存期不足6年,中晚期患者5年生存率仅70%左右。宫颈癌发病机制复杂,是一个多因素、漫长的过程。在体液或组织中定量存在的肿瘤生物标志物是由肿瘤细胞产生的蛋白质,在治疗监测和预测疾病的预后中发挥关键作用。本文主要介绍近年来研究的宫颈癌转移的生物标志物,并强调其潜在的治疗用途。
Cervical cancer is a common malignant tumor,the global incidence is second to breast cancer among women,and the prognosis is poor.According to statistics,the median survival time of patients with cervical cancer is less than 6 years,and the 5-year survival rate of patients with advanced disease is only about 70%.The pathogenesis of cervical cancer is complex,and it is a multi-factor,long process.Tumor biomarkers that are quantitatively present in body fluids or tissues are proteins produced by tumor cells that play a key role in the monitoring and prognosis of disease prognosis.The article focuses on biomarkers of metastasis in cervical cancer studied in recent years and highlights their potential therapeutic use.
作者
江龙凤
陈正徐
JIANG Long-feng;CHEN Zheng-xu(The Second People's Hospital of Hefei,Hefei,Anhui 230011)
出处
《智慧健康》
2019年第17期76-78,共3页
Smart Healthcare
关键词
宫颈癌
转移
肿瘤生物标志物
Cervical cancer
Metastasis
Tumor biomarker
